Promising early results for a new head and neck cancer treatment
This is encouraging research, but the “100% response rate” headline needs some context. Here’s a patient-friendly summary you could share with your community:
Researchers have reported encouraging results from a small clinical trial combining a new form of targeted radiation called Alpha DaRT with the immunotherapy drug pembrolizumab (Keytruda) for people with advanced head and neck squamous cell carcinoma.
Alpha DaRT is quite different from conventional external-beam radiotherapy. Tiny radioactive sources are placed directly into the tumour, where they release alpha particles over a very short distance. The aim is to destroy cancer cells while limiting radiation exposure to surrounding healthy tissue. Pembrolizumab helps the immune system recognise and attack cancer cells.
The headline result is striking: all nine patients who could be evaluated responded to treatment. Four had a complete response, meaning no detectable cancer remained on assessment, while five had a partial response, meaning their cancer shrank significantly. Importantly, researchers reported responses throughout the body, including in lesions that were not directly treated with Alpha DaRT.
Median overall survival was 18.2 months, while median progression-free survival—the time before the cancer began growing again—was 5.4 months. The researchers compared this with historical results for pembrolizumab alone of about 12.3 months overall survival and 3.2 months progression-free survival. However, these are comparisons between different studies, so they cannot prove that the combination is better.
The safety findings were also encouraging. No serious adverse events attributed to Alpha DaRT were reported, and the two Alpha DaRT-related adverse events were considered mild.
So, is this a breakthrough?
It is certainly promising, but it is far too early to say. The most important caution is that the headline “100% response rate” comes from only nine evaluable patients. A response also does not necessarily mean that the cancer has been permanently eliminated. Larger clinical trials with longer follow-up will be needed to establish how effective and safe the treatment really is and which patients are most likely to benefit.
For people living with recurrent, locally advanced or metastatic head and neck cancer, however, research into treatments that combine highly targeted radiation with immunotherapy is an encouraging area to watch.
Read the Targeted Oncology article
As always, reports of experimental treatments shouldn't be taken as individual medical advice. Anyone interested in a clinical trial or new treatment should discuss their circumstances with their oncology team.
